April 08, 2025
In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.
April 08, 2025
The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.
April 08, 2025
ACP 2025. Karol E Watson, MD, PhD, highlighted how traditional approaches to CV care have poorly addressed the unique presentations, risk factors, and pathophysiology of heart disease in women.
April 07, 2025
ACP 2025. Harvard gerontologist and preventive cardiologist Ariela Orkaby, MD, MPH, highlighted the many nuances required in the cardiovascular care of the aging population.
April 07, 2025
Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.
April 07, 2025
Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.
April 05, 2025
ACP 2025. Scripps Clinic's John M Kelso, MD, offered topline updates on all types of allergies including a step-by-step on how to "delabel" patients identified as penicillin-allergic.
April 05, 2025
Foluso A. Fakorede, MD, sketched a disturbing picture of recognition and management of PAD in the US, highlighting stark racial and ethnic disparities and making an urgent call to action.
April 04, 2025
The highest CRC mortality rates occur at the “intersection of race, place, and class," Rachel Issaka, MD, MAS, told internal medicine clinicians at the annual ACP meeting.
April 04, 2025
Dagogo-Jack reviewed alarming data on the damage prediabetes can inflict even decades before a diabetes diagnosis and offered guidance to the internal medicine audience.